Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Mangalam Drugs & Organics Ltd. ( (IN:MANGALAM) ) has issued an update.
Mangalam Drugs & Organics Ltd. announced its unaudited financial results for the quarter ending June 30, 2025, reporting a net loss of Rs. 1,372.80 lakhs, a significant decline compared to a profit in the previous year. The company’s financial performance reflects challenges in the market, with decreased sales and increased expenses impacting profitability, which may concern stakeholders and investors.
More about Mangalam Drugs & Organics Ltd.
Mangalam Drugs & Organics Ltd. operates in the pharmaceutical industry, focusing on the production of active pharmaceutical ingredients (APIs) and intermediates. The company is headquartered in Mumbai, India, and has a manufacturing facility in Vapi, Gujarat.
Average Trading Volume: 6,062
Technical Sentiment Signal: Sell
Current Market Cap: 1.32B INR
For a thorough assessment of MANGALAM stock, go to TipRanks’ Stock Analysis page.